NEW YORK (GenomeWeb News) – SynapDx today announced the completion of a Series A1 financing round that brought in $6 million to support a clinical study in support of the company's test for autism spectrum disorders.

Funds from this round of financing came from North Bridge Venture Partners and General Catalyst Partners.

Southborough, Mass.-based SynapDx is developing a blood-based test that measures RNA expression to differentiate children who have a higher risk for ASDs from those who don't. Its test aims to identify children with ASD by the age of 36 months.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.

In Science this week: the Human Silencing Hub protein complex, and more.